Yesterday, the Senate Judiciary Committee held a hearing on competition and transparency in the prescription drug marketplace, and the criticism of PBMs and their interference was loud. Nearly all members of the bipartisan committee called out PBM monopolies and their anticompetitive tactics. Chairman Chuck Grassley (R-Iowa) and Ranking Member Dick Durbin (D-Ill.) both called out how PBMs are harming local pharmacies and emphasized the need for legislation to move on this bipartisan issue.
One of the panel witnesses was Matthew Pitlick, CEO of the Iowa Pharmacy Association. He spoke to the challenges that pharmacies are facing, and his commentary was echoed by the other four panelists. Some comments were particularly noteworthy, including a dive into the perils of patient steering by Sen. Richard Blumenthal (D-Conn.), and reflections by Sen. Josh Hawley (R-Mo.) on the challenges of vertical integration, who noted Missouri lost 73 independent pharmacies in 2023 alone, highlighting the legislation he has been working on to put a halt to the continued expansion. Sen. Cory Booker (D-N.J.) discussed how middlemen take about 41 cents of every drug dollar, calling the recent FTC settlements with PBMs “kabuki theater” and pushing to break up vertically integrated PBMs, who he blamed for the loss of independent pharmacies. Sen. Katie Britt (R-Ala.) stressed that rural and independent pharmacies need to survive and thrive, and that savings must reach consumers.
You can watch the hearing here.